Stallion Laboratories Private Limited

Stallion Laboratories Private Limited, established on January 18, 1988, is a privately held pharmaceutical formulation manufacturer headquartered in Ahmedabad, Gujarat, India. The company operates under the Corporate Identification Number (CIN) U24231GJ1988PTC010285 and is registered with the Registrar of Companies, Ahmedabad. As of the latest available data, Stallion Laboratories has an authorized capital of ₹10.00 crore and a paid-up capital of ₹2.53 crore.

The company employs over 400 qualified staff members and has a diverse product portfolio, exporting to more than 70 countries. Stallion Laboratories specializes in the manufacturing of tablets, capsules, liquids, and powders, catering to both emerging markets and the U.S. market.

Stallion Laboratories operates two manufacturing facilities:

1. Unit 1: Designed for emerging markets, this facility produces a wide range of pharmaceutical formulations, including tablets, capsules, liquids, and powders.

2. Unit 2: Tailored for the U.S. market, this unit focuses on the production of general tablets and capsules.

Both units adhere to stringent quality control measures and are equipped with modern technology to ensure compliance with international standards.

The leadership team at Stallion Laboratories includes:

• Arvindkumar Jayantilal Thakker: Director

• Vijay Jasvantlal Shah: Director

• Vipulkumar Rajnikant Shah: Director

These individuals have been instrumental in steering the company towards its current position in the pharmaceutical industry.

Stallion Laboratories has made significant strides in regulated markets:

• United States: The company has FDA registrations for its facilities and has filed Abbreviated New Drug Applications (ANDAs) for various products. (fda.report)

• European Union and United Kingdom: While specific regulatory approvals are not detailed, Stallion Laboratories exports to Europe and the UK, indicating compliance with EU and UK regulations.

• Australia and Japan: The company's export activities in these regions suggest adherence to respective regulatory standards, though specific approvals are not specified.

Stallion Laboratories has a strong presence in emerging markets:

• Africa, Latin America, and Southeast Asia: The company exports to over 70 countries, including regions in Africa, Latin America, and Southeast Asia, indicating a broad market reach.

• WHO Prequalification: While specific WHO prequalification status is not mentioned, the company's adherence to WHO Good Manufacturing Practices (GMP) suggests a commitment to quality standards.

Stallion Laboratories demonstrates a diversified geographic strategy:

• Diversification: The company exports to more than 70 countries, reducing dependence on any single market.

• Concentration Risk: With a significant portion of exports in nutritional supplements and advanced diabetes medications, there is a moderate concentration risk.

• Strategic Direction: The focus on both emerging and regulated markets indicates a balanced approach to growth and risk management.

Stallion Laboratories' FDA status includes:

• Facility Registrations: The company has FDA-registered facilities for the manufacture of pharmaceutical products. (fda.report)

• Approved ANDAs: Specific details on approved Abbreviated New Drug Applications (ANDAs) are not provided.

• DMF Filings: Information regarding Drug Master File (DMF) filings is not available.

• Inspection History: The company has undergone FDA inspections, with the most recent Form 483 issued on March 24, 2023.

Stallion Laboratories holds certifications that reflect its commitment to quality:

• WHO GMP: The company operates WHO GMP-approved production facilities, ensuring adherence to international quality standards.

• EU GMP: While specific EU GMP certificates are not detailed, the company's export activities to Europe suggest compliance with EU GMP standards.

In India, Stallion Laboratories complies with regulatory requirements:

• CDSCO Manufacturing Licenses: The company holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), authorizing the production of pharmaceutical formulations.

• State Drug Controller Approvals: Specific approvals from state drug controllers are not detailed but are implied through CDSCO licensing.

• Export NOCs: The company has obtained No Objection Certificates (NOCs) for export, facilitating international trade.

Stallion Laboratories has experienced regulatory scrutiny:

• FDA Form 483: On March 24, 2023, the FDA issued a Form 483 following an inspection of the company's facility in Ahmedabad, India.

• Warning Letters and Import Alerts: No specific warning letters or import alerts are reported in the available data.

In the pharmaceutical formulation sector, Stallion Laboratories faces competition from:

• Top Competitors: Companies such as Sun Pharmaceutical Industries, Cipla, and Dr. Reddy's Laboratories operate in overlapping therapeutic categories.

• Market Share Comparison: Stallion Laboratories holds a 1.0% market share in amino formulations, 0.9% in gliclazide and piperacillin, and 0.5% in lisinopril, indicating a niche presence.

• Head-to-Head Analysis: While larger competitors dominate the market, Stallion Laboratories' focus on niche products allows for specialized market positioning.

Stallion Laboratories' unique strengths include:

• Product Portfolio: A diverse range of products across multiple therapeutic categories, with a significant focus on nutritional supplements and advanced diabetes medications.

• Manufacturing Facilities: State-of-the-art facilities compliant with WHO GMP standards, ensuring high-quality production.

• Regulatory Compliance: Adherence to international regulatory standards, facilitating exports to over 70 countries.

Stallion Laboratories' current strategic direction involves:

• Generics Focus: Emphasis on generic pharmaceutical formulations, particularly in the diabetes and antibiotic segments.

• Future Outlook: Plans to expand into specialty products and biosimilars, leveraging existing manufacturing capabilities and regulatory approvals.

As a supplier, Stallion Laboratories demonstrates:

• Track Record: Over 35 years in the pharmaceutical manufacturing industry, with a consistent export volume of $7.7 million USD across 362 shipments.

• Export Consistency: Regular exports to more than 70 countries, indicating reliability and market acceptance.

• Reliability Indicators: Compliance with international quality standards and regulatory approvals, though recent FDA observations suggest areas for improvement.

Importers should verify the following certifications:

• FDA Registration: Confirm the company's FDA registration status for facility and product approvals.

• WHO GMP Certification: Ensure the manufacturing facilities are WHO GMP certified, indicating adherence to international quality standards.

• EU GMP Certification: Verify compliance with EU GMP standards for products exported to European markets.

• ISO Certification: Check for ISO certifications related to quality management systems.

Before engaging with Stallion Laboratories, consider the following steps:

• Regulatory Compliance: Verify current FDA registrations and WHO GMP certifications.

• Quality Assurance: Review